Currently, Kiniksa Pharmaceuticals International Plc [KNSA] is trading at $36.57, up 2.41%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KNSA shares have gain 9.20% over the last week, with a monthly amount glided 10.45%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $40. Previously, Jefferies started tracking the stock with Buy rating on September 13, 2024, and set its price target to $40. On May 03, 2024, Wells Fargo initiated with a Overweight rating and assigned a price target of $34 on the stock. BofA Securities reiterated its Buy rating and increased its price target to $40 on June 29, 2020. BofA/Merrill initiated its recommendation with a Buy and recommended $25 as its price target on April 01, 2020. Barclays started tracking with a Overweight rating for this stock on March 11, 2019, and assigned it a price target of $26. In a note dated December 12, 2018, Wedbush reiterated an Outperform rating on this stock and boosted its target price from $31 to $33.
This stock has fluctuated between a low of $17.82 and a high of $35.84 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $54 within the next 12 months. Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] shares were valued at $36.57 at the most recent close of the market. An investor can expect a potential return of 47.66% based on the average KNSA price forecast.
Analyzing the KNSA fundamentals
Trailing Twelve Months sales for Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] were 529.33M which represents 44.34% growth. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at 0.01%, Pretax Profit Margin comes in at 0.03%, and Net Profit Margin reading is 0.01%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.01 and Total Capital is 0.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.77 points at the first support level, and at 34.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.06, and for the 2nd resistance point, it is at 37.54.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] is 3.57. Further, the Quick Ratio stands at 3.16, while the Cash Ratio is 1.63. Considering the valuation of this stock, the price to sales ratio is 5.12, the price to book ratio is 5.47 and price to earnings (TTM) ratio is 889.78.
Transactions by insiders
Recent insider trading involved Tessari Eben, CHIEF OPERATING OFFICER, that happened on Sep 04 ’25 when 85271.0 shares were sold. CHIEF OPERATING OFFICER, Tessari Eben completed a deal on Sep 05 ’25 to sell 13389.0 shares. Meanwhile, CHIEF CORP. & COMM. OFFICER Moat Ross sold 3523.0 shares on Sep 04 ’25.
